Posted on 02/03/2023 2:31:47 PM PST by ConservativeMind
A study has directly compared two classes of drugs used to treat type 2 diabetes (T2D) and found that one of the two classes is associated with a greater reduction of major adverse cardiovascular events in men than in women.
The two classes of drugs are SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA). Both classes of medication reduce major adverse cardiovascular events in people with T2D.
Despite women with T2D having a higher risk of developing cardiovascular disease and heart failure than men with T2D, treatment approaches remain the same.
Rsearchers set out to directly compare and report the sex-specific effects of SGLT2i with GLP-1RAs on major adverse cardiovascular events in men and women, with further analyses based on age.
Overall, men dispensed SGLT2i had a 22 percent reduction rate in major adverse cardiovascular events compared to men supplied a GLP-1RA, while in women there was no significant difference between SGLT2i and GLP-1RAs for their effects on major adverse cardiovascular events.
The team also demonstrated for the first time that SGLT2i, in a head-to-head comparison GLP-1RAs, reduces major cardiovascular rates in both older men and women (≥65 years) with T2D, in men with a history of heart failure, and in women with baseline atherosclerotic cardiovascular disease.
Leader of Heart Failure Pharmacology at MIPS and corresponding senior author, Professor Rebecca Ritchie, said there may be a number of reasons women with T2D are more at risk of developing cardiovascular disease and heart failure than men with T2D.
"Typically women with T2D present with greater insulin resistance, endothelial dysfunction, inflammation, abdominal adiposity, body mass index, and blood glucose and cholesterol levels than men with T2D. Additionally, increases in cardiovascular disease and heart failure risk in postmenopausal women suggests an integral role for estrogen in cardioprotection in women," said Professor Ritchie.
(Excerpt) Read more at medicalxpress.com ...
SGLT2 inhibitor
https://en.m.wikipedia.org/wiki/SGLT2_inhibitor
The list of drugs is under “Members.”
It’s a man’s world-get it?
LATER
It only seems that way because women are imaginary
Bookmark
bookmark
bkmk
.
I’m a female, and on Jardiance, which is in that drug class. I don’t know about heart attacks, but I did lose 26 pounds over a two-year period without dieting. My doctor sent me for CAT-scans of the chest and abdomen with dye and contrast last year to make sure there was no other cause for the loss, but found nothing.
I, too, am taking Jardiance. I had the same experience - went to the doc and wanted to know if I had cancer somewhere, because I was losing weight without trying to. He did the tests and said it’s just due to Jardiance. Not long after that he also started me on Ozempic which accelerated the weight loss. I’ve dropped over 60 pounds between the 2 meds.
Wow!! Thanks for your comments. Glad you’ve had good luck with the med combo.
Bkmk
Is this the sort of drug that you only take if you have clinical cardiovascular issues.
This is what I mean by clinical
My reference here is that I take cialis and l-citrilline to enable my blood vessels to expand and contract normally—even though I don’t have any clinical issues
So is SGLT2 inhibitor sort of drug that you only take if you have clinical cardiovascular issues.
No one takes SGLT2 inhibitors for cardio issues.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.